期刊文献+

MRI-R2*定量评价肝铁超负荷患者去铁治疗疗效的研究 被引量:7

Comparison of deferasirox and deferoxamine treatment in iron-overloaded patients: liver iron concentration determined by quantitative MRI-R2 *
原文传递
导出
摘要 目的探讨MRI-R2*定量评价肝铁超负荷患者去铁治疗疗效的价值。方法采用完全随机均衡设计法将24例铁超负荷患者分成2组,地拉罗司组和去铁胺组各12例。地拉罗司组和去铁胺组的剂量分别为40和50mg·kg-1·d-1,所有患者分别在治疗前及治疗后6和12个月行3次肝脏MR检查并测量R,’值。采用配对设计秩和检验分别比较2种药物治疗6及12个月后肝脏R2*值与治疗前的差异,并采用完全随机设计两样本秩和检验分别比较2组患者治疗6、12个月的肝脏R:。变化率(△R2*)及SF变化率(ASF)。结果地拉罗司组治疗前及治疗后6、12个月肝脏R2*值中位数分别为1081、889和712Hz,去铁胺组分别为1042、838和488Hz,治疗前2组患者肝脏R2*值间差异无统计学意义(Z=-0.029,P〉0.05)。地拉罗司治疗12个月的△R2*为-32%,去铁胺组为-58%,差异有统计学意义(Z=-3.060,P〈0.01)。ASF地拉罗司治疗12个月为-15%,去铁胺组为-55%,差异有统计学意义(Z=-2.945,P〈0.01)。结论MIRI-R2*技术能检测去铁疗效,去铁胺和地拉罗司都能有效去除肝铁,且去铁胺的去铁效能优于地拉罗司。 Objective To explore the value of MRI-R2 * and to compare clinical effect of two iron chelators ( deferasirox and deferoxamine) in iron-overloaded patients. Methods By completely randomized balanced design, 24 iron-overloaded patients were randomly divided into 2 groups, which consisted of 12 patients treated with deferasirox and 12 patients treated with deferoxamine. The planned deferasirox dose was 40 mg. kg-1 . d-1 , and the deferoxamine dose was no less than 50 mg. kg-1 . d-1. All patients underwent quantitative MRI at the time points of the primary screening, 6 months and 12 months. Pair Wilcoxon rank sum test was used to compare the differences of liver R2 * values of the 2 groups at various time points respectively. Wilcoxon rank sum test was used to compare the differences of change rate of liver R2* values between the two groups at the time point of 6 months, 12 months, respectively. Results Deferasirox group's liver R: * values of primary screening, 6 months and 12 months were 1081, 889 and 712 Hz, while deferoxamine group's liver R2 * values were 1042, 838 and 488 Hz. There was no statistically significant difference between liver R2 * values of two groups at primary screening ( Z = - 0. 029 ,P 〉 0. 05 ). The change rate of liver R2 * of deferasirox group at 12 month was - 32% , while it was - 58% for the deferoxamine group, and there was statistically significant difference between the two groups ( Z = - 3. 060, P 〈0. 01 ). The change rate of serum ferritin of deferasirox group at 12 month was - 15% , while it was -55% for the deferoxamine group, and there was statistically significant difference between the two groups (Z = -2. 945, P 〈 0.01 ). Conclusion By using MRI-R2*, it suggest that both deferasirox anddeferoxamine can effectively remove liver iron and deferoxamine is superior to deferasirox.
出处 《中华放射学杂志》 CAS CSCD 北大核心 2013年第1期55-59,共5页 Chinese Journal of Radiology
基金 国家自然科学基金资助项目(30960361,81160175) 广西自然科学基金资助项目(2011GXNSFA018226)
关键词 磁共振成像 治疗效果 对比研究 Magnetic resonance imaging Treatment outcome Comparative study
  • 相关文献

参考文献16

  • 1Vermylen C. What is new in iron overload? . Eur J Pediatr, 2008, 167:377-381. 被引量:1
  • 2Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med, 2000, 343:327-331. 被引量:1
  • 3Wood JC. Diagnosis and management of transfusion iron overload : the role of imaging. Am J Hematol, 2007, 82 Suppl 12: 1132-1135. 被引量:1
  • 4Salo S, Alanen A, Leino R, et al. The effect of haemosiderosis and blood transfusions on the T2 relaxation time and I/T2 relaxation rate of liver tissue. Br J Radiol, 2002, 75:24-27. 被引量:1
  • 5Alfistiza JM, Artetxe J, Castiella A, et al. MR quantification of hepatic iron concentration. Radiology, 2004, 230:479484. 被引量:1
  • 6i v. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program, 2009: 215-221. 被引量:1
  • 7St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations. Blood, 2005, 105 : 855-861. 被引量:1
  • 8Ghugre NR, Coates TD, Nelson MD, et al. Mechanisms of tissue- iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med, 2005, 54 : 1185-1193. 被引量:1
  • 9Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2^* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 2005, 106: 1460-1465. 被引量:1
  • 10Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1- year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica,2007, 92 : 1599-1606. 被引量:1

同被引文献58

  • 1张静,程流泉,叶慧义,蔡幼铨,马林,孙非,郭行高.正常肝脏3.0T质子MRS的定量研究[J].中国医学影像技术,2007,23(8):1191-1193. 被引量:11
  • 2Venmylen C.What is new in iron overloadEur J Pediatr,2008,167(4):377-381. 被引量:1
  • 3Angelucci E,Brittenham GM,Mc Laren CE,et al.Hepatic iron concentration and total body iron stores in thalassemia major.N Egnl J Med,2000,343(5):327-331. 被引量:1
  • 4Fischer R,Harmatz PR.Non-invasive assessment of tissue iron overload.Hematology,2009,1(1):215-221. 被引量:1
  • 5Kirk P,Roughton M,Porter JB,et a1.Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major.Circulation,2009,120(20):196l-1968. 被引量:1
  • 6He T,Gatehouse PD,Kirk P,et al.Myocardiac T2*measurement in iron-overloaded thalassemia:an ex vivo study to investigate optimal methods of quantification.Magnetic Resonance in Medicine,2008,60(2):350-356. 被引量:1
  • 7杨正汉,冯逢,王霄英.磁共振成像技术指南.北京:人民军医出版社,2014:104-108. 被引量:2
  • 8Wood JC,Ghugre N.Magnetic resonance imaging assessment of excess iron in thalassemia,sickle cell disease and others iron overload disease.Hemoglobin,2008,32(1):85-96. 被引量:1
  • 9St Pierre TG,Clark PR,Chua-anusorn W,et al.Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.blood,2005,105(2):855-861. 被引量:1
  • 10Wood JC,Enriquez C,Ghugre N,et al.MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients.Blood,2005,106(4):1460-1465. 被引量:1

引证文献7

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部